|
- 文件语言:所有提交给MFDS的文件必须为韩语。企业内部文件可用英文,但现场审核时需能提供韩语翻译件。
- ISO 13485 vs KGMP:虽然ISO 13485是基础,但不能直接替代KGMP。企业必须确保其体系完全满足KGMP的特定要求。
- 风险管理:必须依据ISO 14971标准建立全面的风险管理体系,并贯穿产品全生命周期。
- 临床评价:高风险产品(III/IV类)通常需要在韩国境内进行临床试验。
- 标签与说明书:必须使用韩语标注,并符合MFDS的格式和内容要求。
- 上市后监管(PMS):必须建立完善的不良事件监测、报告和产品召回系统。
- MDSAP审核结果:韩国是MDSAP(医疗器械单一审核程序)的成员。在某些情况下,有效的MDSAP审核报告可以用于申请KGMP的桌面审核,但这通常仅适用于初始审核、变更审核或附加审核,而证书的延续审核通常仍需进行现场审核。
File language: All files submitted to MFDS must be in Korean. Internal documents of the enterprise can be in English, but Korean translations must be provided during on-site audits.
ISO 13485 vs KGMP: Although ISO 13485 is the foundation, it cannot directly replace KGMP. Enterprises must ensure that their systems fully meet the specific requirements of KGMP.
Risk management: A comprehensive risk management system must be established in accordance with the ISO 14971 standard and run through the entire product lifecycle.
Clinical evaluation: High risk products (Class III/IV) typically require clinical trials within South Korea.
Labels and instructions: must be labeled in Korean and comply with the format and content requirements of MFDS.
Post Market Regulation (PMS): A comprehensive adverse event monitoring, reporting, and product recall system must be established.
MDSAP audit result: South Korea is a member of MDSAP (Medical Device Single Audit Program). In some cases, a valid MDSAP audit report can be used to apply for desktop audits of KGMP, but this usually only applies to initial audits, change audits, or additional audits, while certificate continuation audits typically still require on-site audits.
|
|